肝纤维化的分子基础与临床诊治现状

李妍; 陆伦根

doi:10.3969/j.issn.1001-5256.2018.01.001

肝纤维化的分子基础与临床诊治现状

DOI: 10.3969/j.issn.1001-5256.2018.01.001

李妍,
陆伦根

上海交通大学附属第一人民医院消化科

详细信息

中图分类号: R575.2
计量
- 文章访问数: 2133
- HTML全文浏览量: 11
- PDF下载量: 626
- 被引次数: 0
出版历程
- 出版日期: 2018-01-20

Molecular basis of hepatic fibrosis and current status of its diagnosis and treatment

Li Yan,
Lu LunGen

Department of Gastroenterology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China

摘要

摘要: 慢性肝损伤时,肝星状细胞与肝实质细胞、Kupffer细胞、肝窦内皮细胞等多种细胞相互作用,介导细胞外基质沉积与肝窦毛细血管化,启动肝纤维化进程,其本质是肝损伤后的修复反应。肝穿刺活组织检查技术是肝纤维化诊断的金标准,但有一定出血风险及死亡风险。无创性诊断肝纤维化的手段主要包括血清分子标志物、影像学诊断技术以及预测性统计模型等,但其尚不能完全替代肝穿刺活组织检查。目前,肝纤维化的治疗主要针对原发疾病、以肝星状细胞为靶点的药物研发、以细胞外基质合成/降解平衡为靶点的药物研发等方面。研究肝纤维化分子机制,为探索肝纤维化治疗提供了坚实的理论基础。
- 肝硬化 /
- 诊断 /
- 治疗 /
- 述评
Abstract: During the process of acute or chronic liver injury, hepatic stellate cells interact with various types of cells such as hepatic parenchymal cells, Kupffer cells, and liver sinusoidal endothelial cells to mediate extracellular matrix deposition and sinusoid capillarization and thus initiate the process of hepatic fibrosis. The nature of hepatic fibrosis is repair response after liver injury. Liver biopsy is regarded as the gold standard for the diagnosis of hepatic fibrosis; however, it is generally associated with the risk of bleeding and even death. Noninvasive diagnostic methods for liver fibrosis mainly include serum biomarkers, imaging techniques, and predictive statistical model, but such methods cannot completely replace liver biopsy. At present, the treatment of hepatic fibrosis focuses on the research and development of new drugs targeting primary disease, hepatic stellate cells, or balance of extracellular matrix synthesis/degradation. The research on the molecular mechanism of hepatic fibrosis provides a solid theoretical basis for exploring the treatment of hepatic fibrosis.
- liver cirrhosis /
- diagnosis /
- therapy /
- editorial

HTML全文

参考文献(32)

[1]FRIEDMAN SL.Hepatic stellate cells:protean, multifunctional, and enigmatic cells of the liver[J].Physiol Rev, 2008, 88 (1) :125-172.

[2]FRIEDMAN SL.Mechanisms of hepatic fibrogenesis[J].Gastroenterology, 2008, 134 (6) :1655-1669.

[3]DUFFIELD JS, FORBES SJ, CONSTANDINOU CM, et al.Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair[J].J Clin Invest, 2005, 115 (1) :56-65.

[4]NOVO E, PAROLA M.The role of redox mechanisms in hepatic chronic wound healing and fibrogenesis[J].Fibrogenesis Tissue Repair, 2012, 5 (Suppl 1) :s4.

[5]DUBUISSON L, DESMOULIERE A, DECOURT B, et al.Inhibition of rat liver fibrogenesis through noradrenergic antagonism[J].Hepatology, 2002, 35 (2) :325-331.

[6]TIAN X, ZHAO C, GUO J, et al.Carvedilol attenuates the progression of hepatic fibrosis induced by bile duct ligation[J].Biomed Res Int, 2017, 2017:4612769.

[7] ARAU'JO JU'NIOR RF, GARCIA VB, LEITAO RF, et al.Carvedilol improves inflammatory response, oxidative stress and fibrosis in the alcohol-induced liver injury in rats by regulating Kuppfer cells and hepatic stellate cells[J].PLo S One, 2016, 11 (2) :e0148868.

[8]GRANT A, NEUBERGER J.Guidelines on the use of liver biopsy in clinical practice.British Society of Gastroenterology[J].Gut, 1999, 45 (Suppl 4) :iv1-iv11.

[9]ROCKEY DC, CALDWELL SH, GOODMAN ZD, et al.Liver biopsy[J].Hepatology, 2009, 49 (3) :1017-1044.

[10]SCHIAVON LDE L, NARCISO-SCHIAVON JL, de CARVALHO-FILHO RJ.Non-invasive diagnosis of liver fibrosis in chronic hepatitis C[J].World J Gastroenterol, 2014, 20 (11) :2854-2866.

[11]JIN B.Extracellular matrix and liver diseases[J].World Chin J Dig, 2002, 10 (1) :63-64. (in Chinese) 金博.细胞外基质与肝脏肿瘤[J].世界华人消化杂志, 2002, 10 (1) :63-64.

[12]NEVES LB, CATARINO RM, SILVA MR, et al.Increased serum levels of laminin in the experimental cirrhosis induced by carbon tetrachloride[J].Arq Gastroenterol, 2003, 40 (3) :173-176.

[13]BECKER L, SALAMEH W, SFERRUZZA A, et al.Validation of hepascore, compared with simple indices of fibrosis, in patients with chronic hepatitis C virus infection in United States[J].Clin Gastroenterol Hepatol, 2009, 7 (6) :696-701.

[14]DEGOS F, PEREZ P, ROCHE B, et al.Diagnostic accuracy of Fibro Scan and comparison to liver fibrosis biomarkers in chronic viral hepatitis:a multicenter prospective study (the FIBROSTIC study) [J].J Hepatol, 2010, 53 (6) :1013-1021.

[15]ZHANG D, LI P, CHEN M, et al.Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease using acoustic radiation force impulse elastography[J].Abdom Imaging, 2015, 40 (4) :723-729.

[16]ADAMS LA, GEORGE J, BUGIANESI E, et al.Complex noninvasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease[J].J Gastroenterol Hepatol, 2011, 26 (10) :1536-1543.

[17]SHAH AG, LYDECKER A, MURRAY K, et al.Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease[J].Clin Gastroenterol Hepatol, 2009, 7 (10) :1104-1112.

[18]CALES P, VEILLON P, KONATEA, et al.Reproducibility of blood tests of liver fibrosis in clinical practice[J].Clin Biochem, 2008, 41 (1-2) :10-18.

[19]ROSSELLI M, Mac NAUGHTAN J, JALAN R, et al.Beyond scoring:a modern interpretation of disease progression in chronic liver disease[J].Gut, 2013, 62 (9) :1234-1241.

[20]MANNE V, AKHTAR E, SAAB S.Cirrhosis regression in patients with viral Hepatitis B and C:a systematic review[J].J Clin Gastroenterol, 2014, 48 (9) :e76-e84.

[21]MARCELLIN P, GANE E, BUTI M, et al.Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B:a 5-year open-label follow-up study[J].Lancet, 2013, 381 (9865) :468-475.

[22]PAN CQ, CHAN S, TRINH H, et al.Similar efficacy and safety of tenofovir in Asians and non-Asians with chronic hepatitis B[J].World J Gastroenterol, 2015, 21 (18) :5524-5531.

[23]TSAI NC, MARCELLIN P, BUTI M, et al.Viral suppression and cirrhosis regression with tenofovir disoproxil fumarate in Asians with chronic hepatitis B[J].Dig Dis Sci, 2015, 60 (1) :260-268.

[24]D'AMBROSIO R, AGHEMO A, RUMI MG, et al.A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis[J].Hepatology, 2012, 56 (2) :532-543.

[25]TROEGER JS, MEDERACKE I, GWAK GY, et al.Deactivation of hepatic stellate cells during liver fibrosis resolution in mice[J].Gastroenterology, 2012, 143 (4) :1073-1083.

[26]HAO H, ZHANG D, SHI J, et al.Sorafenib induces autophagic cell death and apoptosis in hepatic stellate cell through the JNK and Akt signaling pathways[J].Anticancer Drugs, 2016, 27 (3) :192-203.

[27]CALVARUSO V, MAIMONE S, GATT A, et al.Coagulation and fibrosis in chronic liver disease[J].Gut, 2008, 57 (12) :1722-1727.

[28]ZHU L, CHENG M, LIU Y, et al.Thymosin-β4 inhibits proliferation and induces apoptosis of hepatic stellate cells through PI3K/AKT pathway[J].Oncotarget, 2017, 8 (40) :68847-68853.

[29]PALUMBO-ZERR K, ZERR P, DISTLER A, et al.Orphan nuclear receptor NR4A1 regulates transforming growth factor-βsignaling and fibrosis[J].Nat Med, 2015, 21 (2) :150-158.

[30]YANG D, LI L, QIAN S, et al.Evodiamine ameliorates liver fibrosis in rats via TGF-β1/Smad signaling pathway[J].J Nat Med, 2017.[Epub ahead of print]

[31]TAKEMURA S, AZUMA H, OSADA-OKA M, et al.S-allylglutathione improves experimental liver fibrosis by regulating Kupffer cell activation in rats[J].Am J Physiol Gastrointest Liver Physiol, 2017.[Epub ahead of print]

[32]XIE WF, LIN Y.Degradation of extracellular matrix and hepatic fibrosis therapy[J].World Chin J Dig, 2002, 10 (1) :61-63. (in Chinese) 谢渭芬, 林勇.细胞外基质降解与肝脏纤维化治疗[J].世界华人消化杂志, 2002, 10 (1) :61-63.

施引文献

资源附件(0)

访问统计